Fundsmith LLP boosted its position in Idexx Laboratories Inc. (NASDAQ:IDXX) by 6.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,469,336 shares of the company’s stock after buying an additional 258,657 shares during the period. Idexx Laboratories makes up 6.6% of Fundsmith LLP’s holdings, making the stock its 7th largest position. Fundsmith LLP owned 4.99% of Idexx Laboratories worth $415,023,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. State Treasurer State of Michigan boosted its position in shares of Idexx Laboratories by 0.3% in the second quarter. State Treasurer State of Michigan now owns 35,900 shares of the company’s stock valued at $3,334,000 after buying an additional 100 shares during the last quarter. FCG Advisors LLC boosted its position in shares of Idexx Laboratories by 4.8% in the second quarter. FCG Advisors LLC now owns 2,935 shares of the company’s stock valued at $273,000 after buying an additional 135 shares during the last quarter. IFP Advisors Inc boosted its position in shares of Idexx Laboratories by 18.1% in the second quarter. IFP Advisors Inc now owns 1,203 shares of the company’s stock valued at $112,000 after buying an additional 184 shares during the last quarter. Calvert Investment Management Inc. boosted its position in shares of Idexx Laboratories by 3.8% in the second quarter. Calvert Investment Management Inc. now owns 5,397 shares of the company’s stock valued at $501,000 after buying an additional 199 shares during the last quarter. Finally, Seaward Management Limited Partnership boosted its position in shares of Idexx Laboratories by 1.1% in the second quarter. Seaward Management Limited Partnership now owns 18,230 shares of the company’s stock valued at $1,692,000 after buying an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 91.71% of the company’s stock.

Institutional Ownership by Quarter for Idexx Laboratories (NASDAQ:IDXX)

Shares of Idexx Laboratories Inc. (NASDAQ:IDXX) opened at 110.21 on Monday. The firm’s 50-day moving average is $110.49 and its 200 day moving average is $100.57. Idexx Laboratories Inc. has a 12 month low of $63.48 and a 12 month high of $117.84. The firm has a market capitalization of $9.88 billion, a P/E ratio of 46.94 and a beta of 0.48.

Idexx Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, November 1st. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. The company earned $448.30 million during the quarter, compared to the consensus estimate of $448.60 million. Idexx Laboratories had a net margin of 12.36% and a negative return on equity of 788.91%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.48 earnings per share. On average, equities research analysts anticipate that Idexx Laboratories Inc. will post $2.38 EPS for the current year.

Several brokerages have recently weighed in on IDXX. Canaccord Genuity set a $125.00 price objective on Idexx Laboratories and gave the company a “buy” rating in a report on Saturday, October 15th. Zacks Investment Research upgraded Idexx Laboratories from a “hold” rating to a “buy” rating and set a $121.00 price objective for the company in a report on Thursday, August 4th. Stifel Nicolaus reiterated a “buy” rating and issued a $120.00 target price (up from $92.00) on shares of Idexx Laboratories in a research note on Wednesday, August 3rd. Finally, Northcoast Research upgraded shares of Idexx Laboratories from a “sell” rating to a “neutral” rating in a research note on Wednesday, August 3rd. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $105.20.

In other Idexx Laboratories news, Director Rebecca M. Henderson sold 9,924 shares of the company’s stock in a transaction dated Thursday, August 25th. The shares were sold at an average price of $110.43, for a total value of $1,095,907.32. Following the completion of the sale, the director now directly owns 16,678 shares of the company’s stock, valued at approximately $1,841,751.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Jonathan W. Ayers sold 40,000 shares of the company’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $107.85, for a total transaction of $4,314,000.00. The disclosure for this sale can be found here. Insiders own 2.79% of the company’s stock.

Idexx Laboratories Company Profile

5 Day Chart for NASDAQ:IDXX

Receive News & Stock Ratings for Idexx Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories Inc. and related stocks with our FREE daily email newsletter.